Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Financings

ROCKET DOCTOR AI INC. ANNOUNCES LISTED ISSUER FINANCING EXEMPTION (LIFE) NON-BROKERED PRIVATE PLACEMENT

By The Northwire Desk — AI Analysis Jan 09, 2026 · 08:00 AIDR · 0.76 Rocket Doctor AI Inc.
AIDR · Price

Executive Summary

  • Rocket Doctor AI Inc. announced a non‑brokered private placement of at least 4,285,715 units at $0.70 per unit, targeting gross proceeds of a minimum of approximately $3 million.
  • Each unit consists of one common share and one warrant to purchase an additional common share at $0.85 exercisable for 12 months after closing; the company may also issue up‑to‑8% finder’s fees and non‑transferable warrants on the proceeds.
  • Net proceeds are earmarked for digital marketing, customer acquisition, operating & administrative expenses (including salaries), research & development, and general working capital.

Key Details

  • Units Offered: Minimum 4,285,715 units
  • Price per Unit: $0.70
  • Minimum Gross Proceeds: ≈ $3,000,000
  • Unit Composition:
  • 1 common share
  • 1 warrant to purchase 1 additional common share at an exercise price of $0.85 (exercisable for 12 months post‑closing)
  • Financing Exemption: Listed issuer financing exemption under NI 45‑106 Part 5A (LIFE Exemption), available to Canadian investors outside Quebec; no hold period required.
  • Potential Finder’s Fee: Up to 8% of aggregate gross proceeds, payable upon closing.
  • Additional Warrants: Non‑transferable warrants equal to up to 8% of units issued, exercisable at $0.85 within 12 months from the Closing Date.
  • Use of Proceeds:
  • Digital marketing & customer acquisition
  • Operating and administrative expenses (including salaries)
  • Research & development
  • General working capital
  • Closing Timeline: Expected on or about January 19, 2026, subject to receipt of minimum subscriptions and required approvals (e.g., CSE approval).
  • Offering Documentation: Available at www.sedarplus.ca and the company website (www.rocketdoctor.ai).

Notable Quotes

  • “We are pleased to announce this financing, which will enable us to accelerate our growth initiatives, expand our AI‑driven healthcare platform, and better serve underserved communities,” – Dr. Essam Hamza, CEO.
Read the original news release →

More from Rocket Doctor AI Inc.

Jun 30, 2026 · 08:00

Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members

M&A / Property Jun 23, 2026 · 08:00

AI-driven telemedicine platform expanding U.S. payer network, but burning cash with a going concern warning.

M&A / Property Jun 18, 2026 · 08:00

AI-driven telehealth platform scaling U.S. payer network, but burning cash and diluting equity to fund marketing.

M&A / Property Jun 16, 2026 · 08:00

AI-driven telehealth platform scaling U.S. payer access while burning cash to fund growth and R&D.

Other Jun 08, 2026 · 08:00

Rocket Doctor AI Launches a Strategic Marketing Partnership with Rick Ware Racing and FINTEKK AP for the 2026 NASCAR Cup Series, NHRA (National Hot Rod Association), World Supercross Championship, AFT (AMA - American Flat Track) and other Nationally telev

M&A / Property Jun 02, 2026 · 08:00

AI Virtual Care Platform Accelerates U.S. Visits and Secures Cash Runway, But Margin Compression and Going Concern Doubts Loom

Earnings